Antikor

EQUITY

Company overview

Next-generation Antibody Fragment Drug Conjugates

Maturity

Prototyping, preclinical

Sector

Drug Discovery

Market

Cancer therapeutics

Goal

£500,000.00

You can indicate your investment interest in this opportunity without any commitment.

Getting rid of chemotherapy

If you know anyone who has gone through chemotherapy you probably know it means an endless stream of nasty side effects: hair loss, kidney trouble, constant nausea, memory loss… A pretty terrible experience

Strangely, chemotherapy actually means taking drugs designed to kill your own cells. Naturally, they are designed to kill fast-growing, abnormal cells more than healthy cells, but essentially when you’re in chemo you are receiving controlled doses of deadly poisons.

Since getting the dose right is the key to chemotherapy, a major problem with it has always been the delivery method. Chemo drugs are meant to kill just a few select cells located in a very small part of your body (a tumor is typically the size of a wart, and is pretty well hidden – for example, somewhere in your uterus); but to get the drugs to where they’re supposed to act, they are released in your bloodstream, meaning they actually end up pretty much all around your body.

” A bit like using precision sniping instead of carpet-bombing. “

  • Click to keep reading (2 min more)

    But there’s a major complication: these cell-killing drugs are typically not very soluble, which makes them hard to move around the body. Take a substance very soluble in water, such as sugar: mix it in your blood and it will get pretty much anywhere. But imagine a substance that is more like tar… you would need to inject huge doses so that at least a bit of that insoluble, sticky stuff ends up actually getting through to the tumour.

    That’s why chemo makes you lose your hair, or causes long-term damage to your heart: these powerful, poisonous drugs that are meant to destroy your tumor actually end up stuck to your hair follicles, heart cells or neurons, and kill them.

    So… how do we improve chemotherapy?

    An obvious idea would be hiding these dangerous drugs inside a vehicle that is smart enough to deliver them exclusively to cancerous cells, instead of releasing huge amounts of poisonous drugs into your bloodstream – a bit like using precision sniping instead of carpet-bombing.

    Sounds interesting? Then meet Immuno Oncology, a whole new industry with a market forecast of $34bn by 2024 (size comparison: Google +Facebook’s combined US advertising revenue in 2016 was $38bn).

    Immuno Oncology is based on the use of antibodies: these wonderful proteins created by the immune system, with the mission of attaching themselves to something very specific and making the body kill it.

    Antibody Drug Conjugates (ADC’s) are simply an antibody with a potent cell-killer as a payload. The antibody gets stuck to the cancer cell, the drug kills it, and no healthy cell is harmed in the process.

    ADC’s have been a huge breakthrough in cancer therapy, but now Imperial College spin-out Antikor is aiming to improve the model with the development of Fragment Drug Conjugates (FDC’s). FDC’s retain the ADC’s specificity and killing capability, but since they are much smaller (ADC’s are rather bulky!) Antikor claim they will penetrate faster and further inside the tumours and kill them more effectively.

    This improvement on an already impressive technology is being developed into a treatment for Gastric Cancer, a market expected to reach $4.4bn by 2025.

Daniel Oliver

Capital Cell CEO, Biologist and Crowdfunding Expert.
See my LinkedIn
daniel-project

What differentiates the company

HIGHLIGHTS

  • Fragment drug conjugates (FDC) greatly improve delivery of drug payload in malignant cells compared to traditional ADCs.
  • FDCs need lower doses to act, they are better tolerated and have fewer side effects.
  • ADC market (currently $2.0B) expected to more than double by 2020.
  • Strong IP to protect products until 2034.

What our experts say  

THIS PROJECT HAS BEEN REVIEWED BY THE BIOEXPERT NETWORK OF 500+ PHD LEVEL SCIENTISTS, PHYSICIANS, IP LAWYERS, CONSULTANTS AND INVESTMENT PROFESSIONALS. THEY HAVE RATED THIS PROJECT BASED ON VARIOUS PARAMETERS, INCLUDING: THE SCIENTIFIC VALIDITY, TEAM EXPERTISE, ROUTE TO MARKET, VALUATION AND INVESTABILITY.

The final ratings  

THESE ARE THE AVERAGE SCORES, TAKEN FROM A VARIETY OF REVIEWS PERFORMED BY THE BIOEXPERT NETWORK AND OUR INTERNAL ANALYTICAL TEAM.

Team

WHAT'S THIS?
THE PROFESSIONAL EXPERTISE OF THE TEAM AND OVERALL STRUCTURE OF THE COMPANY.

Science

WHAT'S THIS?
THE CREDIBILITY OF THE SCIENTIFIC RESEARCH AND DEVELOPMENT, THE STATUS OF THE PATENT AND THE ACCURACY OF THE INFORMATION PRESENTED.

Innovation

WHAT'S THIS?
THE NOVEL MERIT OF THE PROJECT AND COMPARISON OF THE COMPANY TO COMPETITORS.

Business

WHAT'S THIS?
THE MATURITY OF THE COMPANY, AND APPROPRIACY OF THE BUSINESS MODEL, PLAN AND ROUTE TO MARKET.

Finances

WHAT'S THIS?
THE PRESENTATION OF FINANCIAL INFORMATION, INCLUDING PRE-MONEY VALUATION, BALANCE SHEET, FORECAST, EXPECTED ROI, EXIT AND ROI JUSTIFICATION.

Approved by the Bioexpert Network

The BioExpert Network is an independent and exclusive network of industry experts in the sectors of life science and investment. Only proposals which receive the most positive responses, in terms of novel concepts, scientific validity and financial accuracy successfully progress to funding campaign stage on the Capital Cell online platform.

Company Information

Who we are

 

TEAM

Purpose of the project

 

FROM PROBLEM TO SOLUTION

THE PROBLEM

One of the most active areas of cancer therapy R&D is the development of antibody drug conjugates (ADCs). Powerful toxin payloads are attached to whole monoclonal antibodies (MAbs) precisely targeted to the tumour. ADC drugs have failed to live up to their promise due to 3 intrinsic & critical limitations

  • Low potency - MAbs do not conjugate stably with more than 4 payloads.
  • Poor/slow tumour penetration - ADCs are very bulky molecules
  • Toxicity and low therapeutic index – the inevitable consequence of the high ADC doses needed for sufficient efficacy and their long residence time (~1 month) in normal tissues.

THE SOLUTION

Antikor’s technology solves all these problems through a proprietary technology named OptiLink TM Fragment Drug Conjugates (FDCs).

Contact the Company

CONTACT THE COMPANY

Leave a Reply